top of page
A game changer in the detection and treatment of life-threatening diseases, Serva technology is pushing the boundaries of nuclear medicine by identifying new, efficient pathways to develop Actinium-225, a powerful targeted alpha therapy isotope able to treat the deadliest cancers.
Advanced-stage cancer is in remission after just 3 doses of Actinium-225 antibody therapy.
This research was originally published in the December 2016 issue of the Journal of Nuclear Medicine.
Serva is accelerating the production of life-saving medical isotopes like Actinium-225, a promising cancer treatment known as the "rarest drug on Earth,"
to serve the biomedical research community and greater patient population.
DEMAND FOR RADIOISOTOPES
Although over 40 million people benefit every year from the use of medical isotopes, innovation in the field has been restricted by the identification and production of appropriate radioisotopes.
The demand for isotope research and development was a key driver of Serva's involvement with Mayo Clinic and the ASU MedTech Accelerator in April 2022.
Through its Smart Nuclear Materials, powering the production of rare isotopes, Serva supports the potentially dramatic increase in the number of cancer treatment options available.
bottom of page